The Experts below are selected from a list of 1056 Experts worldwide ranked by ideXlab platform
Susan F. Leitman - One of the best experts on this subject based on the ideXlab platform.
-
The effect of repeated stimulated Granulocyte donations on hematopoietic indexes in donors: a 24‐year donor center experience
Transfusion, 2018Co-Authors: James Szymanski, Susan F. Leitman, Yu Ying Yau, James Troendle, Hong Hong, Cathy CantilenaAbstract:BACKGROUND Short- and long-term effects of mobilization regimens in hematopoietic stem cell and Granulocyte donors have been well characterized. In this study, we examined the longitudinal hematopoietic changes related to repeat stimulated Granulocyte donation. STUDY DESIGN AND METHODS Complete blood counts for consecutive Granulocyte donors between October 1994 and May 2017 were compared to unstimulated Granulocyte donors. Plateletpheresis donors served as controls. The longitudinal change in preCollection white blood cell (WBC) counts for these donor groups were modeled using a linear mixed-effects model. The investigated variables were Granulocyte, lymphocyte, and monocyte counts and the Granulocyte Collection yield. Contrasts were performed to explore the effect of donation number on preCollection counts. RESULTS For the Granulocyte-colony-stimulating factor plus dexamethasone (G-CSF/Dex)-stimulated group, both the Granulocyte and the lymphocyte counts decreased 6.51 × 109 /L (-23.1%, p < 0.001) and 0.21 × 109 /L (-20.4%, p < 0.001), respectively, between Donation 1 and Donation 20. This effect was still present at the 3- to 4-year interval (b = -0.0008313, SE = 0.00029, p = 0.004). For the unstimulated donor group between Donation 1 and Donation 20, the lymphocyte count decreased by 0.62 × 109 /L (-51.5%, p < 0.001). This effect was only significant up to Year 2 (b = -0.0026, SE = 0.0010, p = 0.013). CONCLUSIONS Past Granulocyte donations were found to have a statistically strong negative effect on preCollection Granulocyte counts and lymphocyte counts and decreased Granulocyte yield both in the G-CSF/Dex-stimulated donors and the unstimulated donors. In this statistical model, for both these groups, the effect of past donations on Granulocyte and WBC counts were still detectable 2 years later.
-
Preparation of Granulocyte concentrates by apheresis: Collection modalities in the USA
Vox sanguinis, 2011Co-Authors: Ronald G. Strauss, Susan F. Leitman, Harvey G. Klein, Benjamin Lichtiger, Thomas H. Price, F. Martinez, Henk W. Reesink, Simon PanzerAbstract:A previous International Forum (IF) addressed Collection modalities of Granulocytes (i.e. neutrophils) for supportive therapy (Vox Sang 2010; 88:567–575). Contributions to this IF came only from European centres because physicians representing centres from the United States of America (USA) elected not to participate. However, after publication of the IF, it was suggested by Professor Strauss that other centres from the USA be invited to describe their Collection modalities, because it was anticipated that there might be noteworthy differences in practices between centres in Europe and the USA. Indeed, some differences have now become apparent, based on responses from four different centres in the USA. Question 1 Donor selection Do you collect Granulocytes exclusively from your pool of healthy blood donors or do you also include the patients’ relatives as donors? When selecting the donor, do you predominantly select CMV-negative donors for CMV-negative recepients? Question 2 Mobilization regimen Does your national law allow the administration of G-CSF to unrelated donors Does your national law allow the administration of G-CSF to related donors Which dose of G-CSF is administered to the donors and at how many hours before donation? Do you combine G-CSF with steroids? If yes, at which dose and which kind of steroids – prednisolone or dexamethason (DXM)? If steroids are given alone, at how many hours before Collection? prednisolone (dosage)? DXM (dosage)? Question 3 Frequency of donations Do you restrict the frequency of donations if the donor has been primed with G-CSF, steroids or both? What are your regulations concerning the accumulation of HES in the donor? Question 4 Sedimentation agents High- (Hetastarch, HS) and low molecular weight hydroxyethyl starch (Pentastarch PS) are used as sedimentation agents to enhance Granulocyte Collection. Which kind of hydroxyethyl starch is used at your institution for Granulocyte Collection? Question 5 Compatibility tests Do you respect or ignore the ABO and Rhesus match between donor and recipient? Do D-negative women younger than 50 years receive Granulocytes only from D-negative donors? Question 6 Screening for leucocyte antibodies Because of the risk of TRALI, the ISBT working party has recommended to screen donor and recipient for the leucocyte antibodies. In case of positivity of either donor or recipient, a crossmatch between the plasma/serum of the positive individual and the leucocytes of the negative individual was recommended [4]. Do you screen or crossmatch the donor and recipient for leucocyte antibodies (HLA and HNA)? If positive, which consequences are drawn? Do you routinely reduce the plasma donations from female donors? In the USA, G-CSF is not approved by the FDA to be given to apheresis donors for mobilizing Granulocytes. Furthermore, ‘Granulocytes apheresis’ are not listed as an FDA-licensed product. In three of the four responding USA centres, the dose of G-CSF given to all donors before each Collection is a standard one of 480 μg, whereas it is 600 μg in the fourth centre. In all centres, G-CSF is combined with oral dexamethasone (8 mg). In contrast, six European centres give varying doses of G-CSF according to the donors’ body weight, and only two apply a standardized dose of 300 μg G-CSF to all donors. Further, some European centres use only steroids for donor stimulation, while others use G-CSF alone. Although steroids alone are used by some of the other centres in the USA, they are not used alone by the four responding centres because Granulocyte yields are substantially lower than those when donors are stimulated with combined G-CSF + dexamethasone. Moreover, the frequency of donations per donor is significantly less frequent in Europe than in the USA. Another difference is that in the USA, high molecular weight HES is used in three of the four centres because Granulocyte yields are superior when compared to lower molecular weight HES, whereas this higher molecular weight HES is applied in only three European centres because of preference in Europe for the lower molecular weight formulation of HES. In two of the three USA centres that answered the question concerning ABO and Rh-D compatibility, ABO compatibility is required – similarly to Europe, where it is required in all but one centre. In two of the four USA centres, Rh-D compatibility is required. Screening donors for HLA and/or HNA antibodies is rarely performed, either in the USA or Europe. The apparent variation in methods for collecting Granulocyte concentrates by apheresis requires interested readers to study all available reports and then to select the procedure that best suits their practice. This challenging field is certainly open for further research, and this IF may serve as a stimulating basis for further investigations. Guest Editor Ronald G. Strauss Professor Emeritus of Pathology & Pediatrics University Of Iowa College of Medicine Tel.: 1-319-338-8071 Fax: 1-319-356-0331 E-mail: ude.awoiu@ssuarts-dlanor International Forum Editors Simon Panzer University of Vienna Department Blood Group Serology and Transfusion Medicine Waahringer Gurtel 18-20 A-1090 Vienna, Austria E-mails: ta.ca.neiwinudem@reznap.nomis; ln.tenalpnpk@muroflanoitanretni and Henk W. Reesink Academic Medical Center Department Gastroenterology and Hepatology Amsterdam The Netherlands E-mails: ln.tenalpnpk@muroflanoitanretni; ln.cma@kniseer.w.h
-
Gravity sedimentation of granulocytapheresis concentrates with hydroxyethyl starch efficiently removes red blood cells and retains neutrophils.
Transfusion, 2010Co-Authors: Barbara J. Bryant, Yu Ying Yau, Phyllis Byrne, David F. Stroncek, Susan F. LeitmanAbstract:BACKGROUND: Transfusion of granulocytapheresis concentrates can be limited by the volume of incompatible donor red blood cells (RBCs) in the component. Efficient reduction of RBCs in Granulocyte units would result in safe transfusion of RBC-incompatible units. STUDY DESIGN AND METHODS: Granulocyte concentrates were collected by continuous-flow apheresis from Granulocyte–colony-stimulating factor (G-CSF) and dexamethasone-stimulated volunteer donors, with 6% hydroxyethyl starch (HES) added continuously during apheresis as a RBC sedimenting agent to enhance Granulocyte Collection efficiency. After Collection, the component was placed in a plasma extractor for 4 hours. A sharp line of demarcation between the starch-sedimented RBCs and the Granulocyte-rich supernatant developed, and the supernatant was transferred to a sterilely docked transfer pack. RBC reduction and white blood cell recovery were determined. RESULTS: Gravity sedimentation was performed on 165 Granulocyte concentrates. Mean sedimentation time was 267 minutes (range, 150-440 min). RBC depletion was 92% (range, 71%-99%) with mean residual RBC content of 3.2 ± 1.4 mL. Twelve percent of components contained less than 2 mL of RBCs. Mean Granulocyte and platelet (PLT) recoveries were 80 and 81%, respectively. There were no transfusion reactions or signs of hemolysis after transfusion of 66 RBC-incompatible Granulocyte concentrates (RBC volume, 1.6-8.2 mL). The remaining concentrates were used for topical or intrapleural applications. CONCLUSIONS: RBCs were significantly reduced and Granulocytes and PLTs effectively retained in G-CSF/steroid–mobilized Granulocyte components collected with HES and processed by gravity sedimentation. This procedure allows safe transfusion of RBC-incompatible sedimented Granulocyte units and may be used to expand the pool of available Granulocyte donors for specific recipients.
-
The determinants of Granulocyte yield in 1198 Granulocyte concentrates collected from unrelated volunteer donors mobilized with dexamethasone and Granulocyte-colony-stimulating factor: a 13-year experience.
Transfusion, 2008Co-Authors: Karen Quillen, Yu Ying Yau, Susan F. LeitmanAbstract:Before the mid-1990s, Granulocyte transfusion therapy was limited by Collection techniques that yielded a cell dose that was often marginal. With the introduction of recombinant human Granulocyte–colony-stimulating factor (G-CSF), it was discovered that a single subcutaneous administration of G-CSF in normal donors followed by leukapheresis 12 to 16 hours later harvested three times the number of functionally normal neutrophils compared with corticosteroid pretreatment;1 the addition of corticosteroids resulted in even higher donor neutrophil counts.2 Previous work by our group3,4 and others5,6 using sub-cutaneous G-CSF at 5 μg per kg 18 hours before and 8 mg of oral dexamethasone 12 hours before granulocytapheresis showed that the mean Granulocyte yield ranges from 5.5 × 1010 to 7.2 × 1010. The donor's neutrophil count at the time of leukapheresis is a key determinant of the Granulocyte yield with any stimulation regimen; it ranges from 5.6 × 109 per L with dexamethasone alone to 13.6 × 109 per L with G-CSF alone to 28.9 × 109 per L with combined G-CSF and dexamethasone (G-CSF/dex).3 The purpose of this study was to explore the donor and procedural characteristics that affect neutrophil response to G-CSF/dex and Granulocyte Collection yield. Donor demographic and laboratory variables and the specifics of G-CSF dosing are some of the key variables that we considered.
-
A controlled comparison of the efficacy of hetastarch and pentastarch in Granulocyte Collections by centrifugal leukapheresis
Blood, 1995Co-Authors: Jan Lee, Susan F. Leitman, Harvey G. KleinAbstract:Compared with hetastarch (HS), the low molecular weight analog pentastarch (PS) has been reported to be equally effective for Granulocyte Collection by centrifugal leukapheresis, to result in fewer adverse donor reactions (ADR), and to have a more rapid elimination profile. We prospectively compared the Granulocyte Collection efficiency (GCE), Granulocyte yield, and ADR in 72 randomly paired granulocytapheresis procedures from 36 volunteer donors using the model CS-3000 Plus Blood Cell Separator (CS) and either PS or HS as the sedimenting agent. Paired Collections from each donor allowed us to compare the two agents directly while controlling for intrinsic donor differences. In 33 of 36 (92%) donors, HS procedures were significantly more efficient than PS procedures (P < .001). As an average, HS Collections yielded 2.3 +/- 0.67 x 10(10) Granulocytes at 58% +/- 8.8% GCE, whereas PS procedures resulted in 1.4 +/- 0.76 x 10(10) Granulocytes at 33% +/- 15% GCE. No starch-induced ADR were seen with either agent. For Granulocyte harvests using the CS, (1) in most donors, using HS as the red blood cell sedimenting agent during centrifugal leukapheresis results in significantly higher (nearly twofold) GCE and larger Granulocyte yields in comparison with using PS, (2) ADR were not observed with either agent, and (3) the potential benefit of more rapid PS elimination should be balanced against significantly lower Granulocyte yields.
Gerda Leitner - One of the best experts on this subject based on the ideXlab platform.
-
Granulocyte Collection using a novel apheresis system eases the procedure and provides concentrates of high quality
Transfusion, 2015Co-Authors: Gerda Leitner, Vera Kolovratova, Michaela Horvath, Nina WorelAbstract:Background The latest technical innovation for Granulocyte (PMN) Collections is the fully automated Spectra Optia (Optia) device (TerumoBCT). In a retrospective investigation we evaluated the impact of the technical automation on the product quality in a routine working field. Study Design and Methods A total of 71 Granulocyte Collections (GCs) were collected from either routine random blood donors, mobilized with prednisolone (P; two females/23 males; median age, 42 years; range, 25-63 years), or family donors (three females/12 males; median age, 29 years; range, 21-59 years) who were mobilized with recombinant human Granulocyte–colony-stimulating factor (rHuG-CSF) at a dose of 5 μg/kg body weight. All Collections were performed with the Optia device. Fifty-nine concentrates (GTX) produced with the Cobe Spectra (Cobe; TerumoBCT) served as a historical control. Results In total a mean of 452 ± 60 mL with a mean purity of 83 ± 9.6% PMNs was collected with the Optia. Compared with the Cobe Collections (298 ± 52 mL), the product volumes in general as well as the absolute PMN yield in P-mobilized products were significantly higher with the Optia: PMN count, 1.9 × 1010 ± 0.49 × 1010 versus 1.5 × 1010 ± 0.85 × 1010, respectively (p < 0.05), due to higher white blood cell (WBC) yields. rHuG-CSF–mobilized products showed no significant differences in the absolute WBC (7.2 ± 3.0/Optia vs. 7.0 ± 2.1/Cobe) and PMN (5.9 ± 2.6/Optia vs. 5.7 ± 1.9/Cobe) yield. The PMN purity was equal in both devices (mean, 83%) although it was slightly lower in the rHuG-CSF group (82 ± 9.2%) than in the P group (84 ± 6.2%). In none of the procedures were side effects recorded. Conclusion GC with the fully automated Optia device is safe for donors, is not inferior to its forerunner Cobe Spectra, produces GTX of a high quality, and requires less manpower than the Cobe Spectra.
-
Granulocyte Collection using a novel apheresis system eases the procedure and provides concentrates of high quality.
Transfusion, 2014Co-Authors: Gerda Leitner, Vera Kolovratova, Michaela Horvath, Nina WorelAbstract:Background The latest technical innovation for Granulocyte (PMN) Collections is the fully automated Spectra Optia (Optia) device (TerumoBCT). In a retrospective investigation we evaluated the impact of the technical automation on the product quality in a routine working field. Study Design and Methods A total of 71 Granulocyte Collections (GCs) were collected from either routine random blood donors, mobilized with prednisolone (P; two females/23 males; median age, 42 years; range, 25-63 years), or family donors (three females/12 males; median age, 29 years; range, 21-59 years) who were mobilized with recombinant human Granulocyte–colony-stimulating factor (rHuG-CSF) at a dose of 5 μg/kg body weight. All Collections were performed with the Optia device. Fifty-nine concentrates (GTX) produced with the Cobe Spectra (Cobe; TerumoBCT) served as a historical control. Results In total a mean of 452 ± 60 mL with a mean purity of 83 ± 9.6% PMNs was collected with the Optia. Compared with the Cobe Collections (298 ± 52 mL), the product volumes in general as well as the absolute PMN yield in P-mobilized products were significantly higher with the Optia: PMN count, 1.9 × 1010 ± 0.49 × 1010 versus 1.5 × 1010 ± 0.85 × 1010, respectively (p
-
Administration of prednisolone intravenously or dexamethason orally in random donors reveals equal results in Granulocyte Collection: a single centre experience.
Vox sanguinis, 2011Co-Authors: V. Kolovratova, Jana List, Nina Worel, P. Jilma, Gerda LeitnerAbstract:Since cytokine – mobilization for Granulocyte Collections in random donors – is not licensed in Austria, we investigated in a prospective analysis the effects of prednisolone or dexamethasone (DXM) in 153 donors (35 women/118 men) and in the collected products. Either prednisolone (50 mg) intravenously 4 h before Granulocyte Collection or DXM (8 mg) orally 12 h before Collection was given. Collections were performed with the Cobe Spectra (CardianBCT, Lakewood). We recorded a significantly higher percentage of Granulocytes in the peripheral blood of the DXM. However, the collected number of Granulocytes was equal in both groups.
Julie Goldberg - One of the best experts on this subject based on the ideXlab platform.
-
spectra optia Granulocyte apheresis Collections result in higher Collection efficiency of viable functional neutrophils in a randomized crossover multicenter trial
Transfusion, 2015Co-Authors: Jose A Cancelas, Anand Padmanabhan, Daniel R Ambruso, Neeta Rugg, Nicole D Worsham, Susan L Pinkard, Sharon Graminske, Jennifer Buck, Julie Goldberg, Jerry BillAbstract:Background Granulocyte transfusion from healthy donors is used in the treatment of patients with Granulocyte function defects, or transient neutropenia and severe bacterial or fungal infections resistant to maximal antimicrobial treatment. Study Design and Methods This study evaluated the performance and safety of the newly developed Granulocyte Collection protocol of the Spectra Optia in a prospective, multicenter, open-label, randomized, paired crossover trial compared with the COBE Spectra apheresis system in a population of 32 evaluable healthy subjects. All subjects received Granulocyte–colony-stimulating factor and dexamethasone before Collection. Results Granulocyte procedures from Spectra Optia apheresis procedures had an approximately 23% higher polymorphonuclear (PMN) Collection efficiency (CE) than the COBE Spectra Collections (mean, 53.7% vs. 43.2%; p < 0.01), while the platelet CE (10.9% vs. 10.8%, respectively) and hematocrit (7.4% vs. 7.4%) were comparable between Collections on both devices. Spectra Optia Collections generated a higher total PMN yield per liter of blood processed than those produced by the COBE Spectra (with means of 8.6 × 1010 vs. 6.8 × 1010, respectively). Granulocyte viability was more than 99% with both devices, and chemotaxic and bacterial killing activities of circulating versus collected Granulocytes were similarly preserved. Fewer operator adjustments were required with Spectra Optia and there was no significant difference in the number or intensity of adverse events between instruments. Conclusion CE of the Granulocyte Collection procedure with the Spectra Optia was approximately 10 percentage points higher than with the COBE Spectra, required less operator involvement, and is safe for clinical implementation.
-
Spectra Optia Granulocyte apheresis Collections result in higher Collection efficiency of viable, functional neutrophils in a randomized, crossover, multicenter trial.
Transfusion, 2014Co-Authors: Jose A Cancelas, Anand Padmanabhan, Daniel R Ambruso, Neeta Rugg, Susan L Pinkard, Sharon Graminske, Jennifer Buck, D. Nicole Worsham, Julie GoldbergAbstract:Background Granulocyte transfusion from healthy donors is used in the treatment of patients with Granulocyte function defects, or transient neutropenia and severe bacterial or fungal infections resistant to maximal antimicrobial treatment. Study Design and Methods This study evaluated the performance and safety of the newly developed Granulocyte Collection protocol of the Spectra Optia in a prospective, multicenter, open-label, randomized, paired crossover trial compared with the COBE Spectra apheresis system in a population of 32 evaluable healthy subjects. All subjects received Granulocyte–colony-stimulating factor and dexamethasone before Collection. Results Granulocyte procedures from Spectra Optia apheresis procedures had an approximately 23% higher polymorphonuclear (PMN) Collection efficiency (CE) than the COBE Spectra Collections (mean, 53.7% vs. 43.2%; p
Nina Worel - One of the best experts on this subject based on the ideXlab platform.
-
Granulocyte Collection using a novel apheresis system eases the procedure and provides concentrates of high quality
Transfusion, 2015Co-Authors: Gerda Leitner, Vera Kolovratova, Michaela Horvath, Nina WorelAbstract:Background The latest technical innovation for Granulocyte (PMN) Collections is the fully automated Spectra Optia (Optia) device (TerumoBCT). In a retrospective investigation we evaluated the impact of the technical automation on the product quality in a routine working field. Study Design and Methods A total of 71 Granulocyte Collections (GCs) were collected from either routine random blood donors, mobilized with prednisolone (P; two females/23 males; median age, 42 years; range, 25-63 years), or family donors (three females/12 males; median age, 29 years; range, 21-59 years) who were mobilized with recombinant human Granulocyte–colony-stimulating factor (rHuG-CSF) at a dose of 5 μg/kg body weight. All Collections were performed with the Optia device. Fifty-nine concentrates (GTX) produced with the Cobe Spectra (Cobe; TerumoBCT) served as a historical control. Results In total a mean of 452 ± 60 mL with a mean purity of 83 ± 9.6% PMNs was collected with the Optia. Compared with the Cobe Collections (298 ± 52 mL), the product volumes in general as well as the absolute PMN yield in P-mobilized products were significantly higher with the Optia: PMN count, 1.9 × 1010 ± 0.49 × 1010 versus 1.5 × 1010 ± 0.85 × 1010, respectively (p < 0.05), due to higher white blood cell (WBC) yields. rHuG-CSF–mobilized products showed no significant differences in the absolute WBC (7.2 ± 3.0/Optia vs. 7.0 ± 2.1/Cobe) and PMN (5.9 ± 2.6/Optia vs. 5.7 ± 1.9/Cobe) yield. The PMN purity was equal in both devices (mean, 83%) although it was slightly lower in the rHuG-CSF group (82 ± 9.2%) than in the P group (84 ± 6.2%). In none of the procedures were side effects recorded. Conclusion GC with the fully automated Optia device is safe for donors, is not inferior to its forerunner Cobe Spectra, produces GTX of a high quality, and requires less manpower than the Cobe Spectra.
-
Granulocyte Collection using a novel apheresis system eases the procedure and provides concentrates of high quality.
Transfusion, 2014Co-Authors: Gerda Leitner, Vera Kolovratova, Michaela Horvath, Nina WorelAbstract:Background The latest technical innovation for Granulocyte (PMN) Collections is the fully automated Spectra Optia (Optia) device (TerumoBCT). In a retrospective investigation we evaluated the impact of the technical automation on the product quality in a routine working field. Study Design and Methods A total of 71 Granulocyte Collections (GCs) were collected from either routine random blood donors, mobilized with prednisolone (P; two females/23 males; median age, 42 years; range, 25-63 years), or family donors (three females/12 males; median age, 29 years; range, 21-59 years) who were mobilized with recombinant human Granulocyte–colony-stimulating factor (rHuG-CSF) at a dose of 5 μg/kg body weight. All Collections were performed with the Optia device. Fifty-nine concentrates (GTX) produced with the Cobe Spectra (Cobe; TerumoBCT) served as a historical control. Results In total a mean of 452 ± 60 mL with a mean purity of 83 ± 9.6% PMNs was collected with the Optia. Compared with the Cobe Collections (298 ± 52 mL), the product volumes in general as well as the absolute PMN yield in P-mobilized products were significantly higher with the Optia: PMN count, 1.9 × 1010 ± 0.49 × 1010 versus 1.5 × 1010 ± 0.85 × 1010, respectively (p
-
Administration of prednisolone intravenously or dexamethason orally in random donors reveals equal results in Granulocyte Collection: a single centre experience.
Vox sanguinis, 2011Co-Authors: V. Kolovratova, Jana List, Nina Worel, P. Jilma, Gerda LeitnerAbstract:Since cytokine – mobilization for Granulocyte Collections in random donors – is not licensed in Austria, we investigated in a prospective analysis the effects of prednisolone or dexamethasone (DXM) in 153 donors (35 women/118 men) and in the collected products. Either prednisolone (50 mg) intravenously 4 h before Granulocyte Collection or DXM (8 mg) orally 12 h before Collection was given. Collections were performed with the Cobe Spectra (CardianBCT, Lakewood). We recorded a significantly higher percentage of Granulocytes in the peripheral blood of the DXM. However, the collected number of Granulocytes was equal in both groups.
P. W. Straub - One of the best experts on this subject based on the ideXlab platform.
-
Improved Granulocyte Collection from Normal Donors by Combination of Continuous‐Flow Centrifugation and Filtration Leukapheresis
Transfusion, 2003Co-Authors: J. P. Gmür, J. Deluigi, P. W. StraubAbstract:A total of 30 leukaphereses were performed with the Aminco Cellseparator on 27 healthy donots. Pretreatment by steroids and addition of fluid gelatin to the input line was performed in all runs. The combination of continuous flow centrifugation and filtration leukapheresis (CFC-FL) in nine of the 30 runs resulted in a highly significant increase of the yield to a mean of 59.6 X 1o(9) Granulocytes as compared with a mean of 30.8 X 10(9) Granulocytes obtained with conventional CFC. This significance is valid for the total yield of Granulocytes, the yield per hour of run, or per liter of blood processed. No adverse reaction occurred.
-
improved Granulocyte Collection from normal donors by combination of continuous flow centrifugation and filtration leukapheresis
Transfusion, 2003Co-Authors: J. P. Gmür, J. Deluigi, P. W. StraubAbstract:A total of 30 leukaphereses were performed with the Aminco Cellseparator on 27 healthy donots. Pretreatment by steroids and addition of fluid gelatin to the input line was performed in all runs. The combination of continuous flow centrifugation and filtration leukapheresis (CFC-FL) in nine of the 30 runs resulted in a highly significant increase of the yield to a mean of 59.6 X 1o(9) Granulocytes as compared with a mean of 30.8 X 10(9) Granulocytes obtained with conventional CFC. This significance is valid for the total yield of Granulocytes, the yield per hour of run, or per liter of blood processed. No adverse reaction occurred.
